4 completed, 3 unknown, 1 recruiting, 1 terminated. 4 Phase 3, 3 Phase 1, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Unknown 2, Completed 1, Recruiting 1 |
| Phase 1 | 3 | Completed 2, Unknown 1 |
| Early Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow QL1206: new trials by email Literature Review of QL1206 trials Research Report on QL1206
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® QL1206, Prolia® - Postmenopausal Women With Osteoporosis at High Risk of Fracture | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 278 | 2025-06-27 | 2025-07-14 |
| A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced Xgeva MB09, US-sourced Xgeva, EU-sourced Xgeva - Healthy Volunteers | Phase 1 | Completed | mAbxience Research S.L. | 257 | 2022-03-01 | 2025-01-03 |
| A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis FKS518, US-licensed Prolia (Amgen) - Postmenopausal Osteoporosis | Phase 3 | Completed | Fresenius Kabi SwissBioSim GmbH | 553 | 2021-06-16 | 2025-02-27 |
| Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults QL1206, Prolia® - Healthy People | Phase 1 | Unknown | Qilu Pharmaceutical Co., Ltd. | 144 | 2019-10-31 | 2019-12-30 |
| Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk QL1206, Placebos - Postmenopausal Osteoporosis | Phase 3 | Unknown | Qilu Pharmaceutical Co., Ltd. | 440 | 2019-06-05 | 2019-11-06 |
| To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors QL1206, Xgeva - Bone Metastases | Phase 3 | Unknown | Qilu Pharmaceutical Co., Ltd. | 700 | 2019-04-26 | 2020-09-22 |
| Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy Denosumab, Salpingo-Oophorectomy - Ovarian Carcinoma | Early Phase 1 | Terminated | National Cancer Institute (NCI) | 2 | 2019-03-14 | 2022-06-14 |
| Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults QL1206, Xgeva® - Healthy People | Phase 1 | Completed | Qilu Pharmaceutical Co., Ltd. | 168 | 2018-08-20 | 2019-10-16 |
| Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma Denosumab, Laboratory Biomarker Analysis, Pharmacological Study - Metastatic Osteosarcoma, Recurrent Osteosarcoma | Phase 2 | Completed | Children's Oncology Group | 56 | 2015-11-21 | 2024-01-22 |
Osteoporosis, Postmenopausal (2) · Osteosarcoma (1) · Ovarian Neoplasms (1)
Qilu Pharmaceutical Co., Ltd. (5) · Children's Oncology Group (1) · Fresenius Kabi SwissBioSim GmbH (1) · National Cancer Institute (NCI) (1) · mAbxience Research S.L. (1)
China (5) · Poland (2) · United States (2) · Bulgaria (1) · Canada (1) · Czechia (1) · Estonia (1) · Georgia (1) · Hungary (1) · Israel (1) · Puerto Rico (1)
Katherine A Janeway (1) · Monika Tomaszewska-Kiecana, MD (1) · Powel Brown (1)
N01CN00034 (1), P30CA016672 (1), U10CA180886 (1)